Protective effect of erythropoietin against cisplatin-induced nephrotoxicity in rats: Antigenotoxic and antiapoptotic effect

Drug and Chemical Toxicology

Volumn 35, Issue 1, 2012, Pages 89-95

  Rjiba Touati, Karima ^a   Ayed Boussema, Imen ^a   Bouaziz, Chayma ^a   Belarbia, Anis ^b   Azzabi, Awatef ^b   Achour, Abdelatif ^b   Hassen, Wafa ^a   Bacha, Hassen ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b University Hospital of Sahloul   (Tunisia)

Author keywords

antiapoptotic effect; antigenotoxicity; Cisplatin; erythropoietin; nephroprotection

Indexed keywords

CASPASE 3; CISPLATIN; CREATININE; ERYTHROPOIETIN; HEAT SHOCK PROTEIN 27; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RECOMBINANT ERYTHROPOIETIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DNA DAMAGE; DNA FRAGMENTATION; DOWN REGULATION; ENZYME ACTIVITY; GENOTOXICITY; KIDNEY FAILURE; MALE; NEPHROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; SINGLE DRUG DOSE; UPREGULATION; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTIMUTAGENIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOOD UREA NITROGEN; CISPLATIN; CREATININE; DNA DAMAGE; DNA FRAGMENTATION; DOWN-REGULATION; ERYTHROPOIETIN; KIDNEY; MALE; MUTAGENS; RATS; RATS, WISTAR; RENAL INSUFFICIENCY; UP-REGULATION;

EID: 83155189937     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.3109/01480545.2011.589440     Document Type: Article

References (53)

1. Allcock, G. H., Hukkanen, M., Polak, J. M., Pollock, J. S., Pollock, D. M. (1999). Increased nitric oxide synthase-3 expression in kidneys of deoxycorticosterone acetate-salt hypertensive rats. J Am Soc Nephrol 10:2283-2289.
2. Anand, A. J., Bashey, B. (1993). Newer insight into cisplatin nephrotoxicity. Ann Pharmacother 27:1519-1525.
3. Bagnis, C., Beaufils, H., Jacquiaud, C., Adabra, Y., Jouanneau, C., Le Nahour, G., et al. (2001). Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transpl 16:932-938.
4. Bajorin, D. F., Bosl, G. J., Alcock, N. W., Niedzwiecki, D., Gallina, E., Shurgot, B. (1986). Pharmacokinetics of cisdiamminedichloroplatinum( II) after administration in hypertonic saline. Cancer Res 46:5969-5972.
5. Banath, J. P., Kim, A., Olive, P. (2002). Overnight lysis improves the efficiency of DNA damage detection in the alkaline comet assay. Radiat Res 1155:564-571.
6. Bianchi, R., Buyukakilli, B., Brines, M., Savino, C., Cavaletti, G., Oggioni, N., et al. (2004). Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A 101:823-828.
7. Bradford, M. M. (1976). A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
8. Cai, Z., Manalo, D. J., Wei, G., Rodriguez, E. R., Fox-Talbot, K., Lu, H., et al. (2003). Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 108:79-85.
9. Calvillo, L., Latini, R., Kajstura, J., Leri, A., Anversa, P., Ghezzi, P., et al. (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 100:4802-4806.
10. Casado, P., Zuazua-Villar, P., del Valle, E., Martínez-Campa, C., Lazo, P. S., Ramos, S. (2007). Vincristine regulates the phosphorylation of the antiapoptotic protein HSP27 in breast cancer cells. Cancer Lett 247:273-282.
11. Celik, M., Gokmen, N., Erbayraktar, S., Akhisaroglu, M., Konakc, S., Ulukus, C., et al. (2002). Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A 99:2258-2263.
12. Ciccarelli, R. B., Solomon, M. J., Varshavsky, A., Lippard, S. J.1985). In vivo effects of cis- and trans-diamminedichloroplatinum (II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry 24:7533-7540.
13. Cohen, S. M., Lippard, S. J.2001). Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 67:93-130.
14. Cornelison, T. L., Reed, E.1993). Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 50:147-158.
15. Cory, S., Huang, D. C., Adams, J. M. (2003). The Bcl-2 family: Roles in cell survival and oncogenesis. Oncogene 22:8590-8607.
16. Cory, S., Adams, J. M. (2002). The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2:647-656.
17. Dixon, S., Soriano, B. J., Lush, R. M., Bomer, M. M., Figg, W.D.1997). Apoptosis: Its role in the development of malignancies and its potential as a novel therapeutic target. Ann Pharmcol 31:76-81.
18. Eastman, A. (1999). The mechanism of action of cisplatin: from adducts to apoptosis. In: Lippert, B., (Ed.), Cisplatin: Chem biol of a leading anticancer drug (pp. 111-135). New York: Wiley-VCH.
19. Esposito, C, Pertile, E, Grosjean, F, Castoldi, F, Diliberto, R, Serpieri, N, et al. (2009). The improvement of ischemia/reperfusion injury by erythropoetin is not mediated through bone marrow cell recruitment in rats. Transpl Proc 41:1113-1115.
20. Faubel, S., Ljubanovic, D., Reznikov, L., Somerset, H., Dinarello, C. A., Edelstein, C.L.2004). Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int 66:2202-2213.
21. Fuertesa, M. A., Castillab, J., Alonsoa, C., Perez, J. M. (2003). Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem 10:257-266.
22. Fuster, J. J., Sanz-Gonzalez, S. M., Moll, U. M., Andres, V. (2007). Classic and novel roles of p53: Prospects for anticancer therapy. Trends Mol Med 13:192-199.
23. Green, C. M., Almouzni,G.2002). When repair meets chromatin. First in series on chromatin dynamics. EMBO Rep 3:28-33.
24. Hanigan, M. H., Devarajan, P. (2003). Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther 1:47-61.
25. Heiger-Bernays, W. J., Essigmann, J. M., Lippard, S. J.1990). Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication. Biochemistry 29:8461-8466.
26. Jamieson, E. R., Lippard, S. J.1999). Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99:2467-2498.
27. Jenderny, S., Lin H., Garrett, T., Tew, K. D., Townsend, D. M. (2010). Protective effects of a glutathione disulfide mimetic (NOV-002) against cisplatin induced kidney toxicity. Biomed Pharmacother 64:73-76.
28. Jiang, M., Wei, Q., Pabla, N., Dong, G., Wang, C. Y., Yang, T., et al. (2007). Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol 73:1499-1510.
29. Ljungman, M. (2000). Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. Neoplasia 2:209-225
30. Oren, M. (1999). Regulation of the p53 tumor suppressor protein. J Biol Chem 274:36031-36034.
31. Pabla, N., Dong, Z. (2008). Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int 73:994-1007.
32. Park, S. Y., Lee, S. M., Ye, S. K., Yoon, S. H., Chung, M. H., Choi, J.2006). Benzo[a]pyrene-induced DNA damage and p53 modulation in human hepatoma HepG2 cells for the identification of potential biomarkers for PAH monitoring and risk assessment. Toxicol Lett 167:27-33.
33. Parlakpinar, H., Sahna, E., Ozer, M. K., Ozugurlu, F., Vardi, N., Acet, A. (2002). Physiological and pharmacological concentrations of melatonin protect against cisplatin-induced acute renal injury. J Pineal Res 33:161-166.
34. Pasetto, L. M., D'Andrea, M. R., Brandes, A. A., Rossi, E., Monfardini, S. (2006). The development of platinum compounds and their possible combination. Crit Rev Oncol Hematol 60:59-75.
35. Picada, J. N., Flores, D. G., Zettler, C. G., Marroni, N. P., Roesler, R., Henriques, J. A.P.2003). DNA damage in brain cells of mice treated with an oxidized form of apomorphine. Brain Res Mol Brain Res 114:80-85.
36. Pinzani, V., Bressolle, F., Haug, I. J., Galtier, M., Blayac, J. P., Balmes, P. (1994). Cisplatin-induced renal toxicity and toxicity-modulating strategies: A review. Cancer Chemother Pharmacol 35:1-9.
37. Rashmi, R., Santhosh Kumar, T. R., Karunagaran, D. (2003). Human colon cancer cells differ in their sensitivity to curcumininduced apoptosis and heat shock protects them by inhibiting the release of apoptosis-inducing factor and caspases. FEBS Lett 538:19-24.
38. Schepers, H., Geugien, M., van der Toorn, M., Harm, H., Bart, J. L. K., Vellengaa, E.2005). HSP27 protects AML cells against VP-16- induced apoptosis through modulation of p38 and c-Jun. Exp Hematol 33:660-670.
39. Sharples, E. J., Patel, N., Brown, P., Stewart, K., Mota-Philipe, H., Sheaff, M., et al. (2004). Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15:2115-2124.
40. Sharples, E. J., Yaqoob, M. M. (2006). Erythropoietin in experimental acute renal failure. Nephron Exp Nephrol 104:83-88.
41. Siddik, Z. H.2003). Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279.
42. Simon, F., Scheuerle, A., Calzia, E., Bassi, G., Oter, S., Duy, C. N., et al. (2008). Erythropoietin during porcine aortic balloon occlusioninduced ischemia/reperfusion injury. Crit Care Med 36:2143-2150.
43. Skinner,R.1995). Strategies to prevent nephrotoxicity of anticancer drugs. Curr Opin Oncol 7:310-315.
44. Story, M., Kodym,R.1998). Signal transduction during apoptosis; implications for cancer therapy. Front Biosci 3:365-375.
45. Sun, Y., Zhou, C., Polk, P., Nanda, A., Zhang, J. H.2004). Mechanisms of erythropoietin-induced brain protection in neonatal hypoxiaischemia rat model. J Cereb Blood Flow Metab 24:259-270.
46. Tice, R. R., Agurell, E., Anderson, D., Burlinson, B., Hartmann, A., Kobayashi, Y., et al. (2000). Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35:206-221.
47. Tsuruya, K., Tokumoto, M., Ninomiya, T., Hirakawa, M., Masutani, K., Taniguchi, M., et al. (2003). Antioxidant ameliorates cisplatininduced renal tubular cell death through inhibition of death receptor mediated pathways. Am J Physiol Renal Physiol 285:F208-F218
48. Ueno, M., Masutani, H., Arai, R. J., Yamauchi, A., Hirota, K., Sakai, T., et al. (1999). Thio-redoxin dependent redox regulation of p53- mediated p21 activation. J Biol Chem 274:35809-35815.
49. Vesey, D. A., Cheung, C., Pat, B., Endre, Z., Gobe, G., Johnson, D. W. (2004). Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transpl 19:348-355.
50. Wang, D., Lippard, S. J.2005). Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307-320.
51. Wang, X. W., Zhan, Q., Coursen, J. D., Khan, M. A., Kontny, H. U., Yu, L., et al. (1999). GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci U S A 96:370.
52. Westenfelder, C., Biddle, D. L., Baranowski, RL. (1999). Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 55:808-820.
53. Yang, C. W., Li, C., Jung, J. Y., Shin, S. J., Choi, B. S., Lim, S. W., et al. (2003). Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 17:1754-1755.